[Experimental study of the "'rebound syndrome" following discontinuation of prolonged phenazepam administration and possibilities for preventing it]

Zh Nevropatol Psikhiatr Im S S Korsakova. 1981;81(7):1056-9.
[Article in Russian]

Abstract

Phenazepam given to rats in a daily dose of 2 mg/kg intraperitoneally for a long (30 days) time ceased to produce the sedative effect, and discontinuation of the medication led to development of the so-called "recoil syndrome" characterized by general depression and disturbances of the conditioned-reflex activity. The "recoil syndrome" was distinguished for a selective specificity, since its motor and sensor manifestations were eliminated only by benzodiazepine derivatives (phenazepam, diazepam). Drugs from other chemical slasses (meprobamate, trioxazine, amipazin) did not influence this syndrome.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Anti-Anxiety Agents*
  • Benzodiazepines*
  • Benzodiazepinones / adverse effects*
  • Benzodiazepinones / therapeutic use
  • Chlorpromazine / therapeutic use
  • Conditioning, Classical
  • Depression / etiology
  • Diazepam / therapeutic use
  • Humans
  • Male
  • Meprobamate / therapeutic use
  • Methaqualone / analogs & derivatives
  • Methaqualone / therapeutic use
  • Morpholines / therapeutic use
  • Phenobarbital / therapeutic use*
  • Rats
  • Substance Withdrawal Syndrome / diagnosis*
  • Substance Withdrawal Syndrome / drug therapy

Substances

  • Anti-Anxiety Agents
  • Benzodiazepinones
  • Morpholines
  • Benzodiazepines
  • lonetil M3
  • trimetozine
  • phenazepam
  • Methaqualone
  • Meprobamate
  • Diazepam
  • Chlorpromazine
  • Phenobarbital